Researchers at the Icahn School of Medicine at Mount Sinai in New York are currently enrolling patients for the first clinical trial to investigate the efficacy of immunological therapy for chronic pulmonary sarcoidosis.
According to investigators, the randomized placebo Phase II clinical trial at is designed to assess the safety, tolerability and efficacy of an antibody directed against macrophage colony-stimulating factor (m-CSF), a protein associated with the development of sarcoidosis.
“This study has both clinical and basic science applications,” said Adam Morgenthau, MD, principal investigator of the study and director of the Sarcoidosis Clinic and the Alvin S. Teirstein Sarcoidosis Support Group at Mount Sinai.
“In addition to determining whether patients’ symptoms improve with this treatment, we will examine cell signaling pathways and immune responses in the trial participants which will help us better understand the biology of sarcoidosis and ultimately lead to the development of therapies that target the immune response.”
To be eligible, patients must be taking corticosteroids daily for chronic pulmonary sarcoidosis and lung impairment. Interested individuals should email the Clinical Trials Office or call 212-241-9538.
